Impulse Dynamics announced today that it raised $136 million in financing to accelerate its investment in its heart failure therapy.
Perceptive Advisors, Redmile Group, Alger and Hobart Healthcare led the financing round. The company expects it to accelerate investment in global commercialization, technology, product innovation and clinical evidence development.
Marlton, New Jersey–based Impulse Dynamics plans to use funds to support, among other things, its INTEGRA-D and AIM HIGHer trials. The company develops the Optimizer Smart Mini system to deliver cardiac contractility modulation (CCM) therapy to the heart. It significantly improves heart contraction to allow more oxygen-rich blood to push out through the body.
INTEGRA-D evaluates the combination of the company’s proprietary CCM therapy with implantable cardioverter defibrillator (ICD) therapy. All this comes through a single device — the Impulse Dynamics Optimizer Integra CCM-D system.
AIM HIGHer evaluates the safety and efficacy of CCM therapy in patients with symptomatic heart failure with an ejection fraction (EF) of 40%-60%. The trial has enrollment underway already, the company said.
“This round of funding will accelerate our business, both commercially and with our pipeline of advanced technology innovation,” said Jason Spees, CEO of Impulse Dynamics. “We continue to make commercial progress globally with more than 9,000 heart failure patients implanted with CCM therapy and millions more who can benefit. We are also getting closer to significantly impacting the implantable cardioverter defibrillator (ICD) market with successful enrollment in our INTEGRA-D clinical trial on the Optimizer Integra CCM-D system.
“Most patients who currently receive a standard ICD get lifesaving benefits from the defibrillator but still struggle with HF symptoms. With CCM-D, these patients will be able to get the lifesaving benefits of a defibrillator combined with HF symptom relief from CCM in one device.”